|
BRZL, EFIR, PSTI, BPAX, MYOS, NEXS
Our Stocks to Watch tomorrow include Brazos International Exploration Inc. (OTCBB: BRZL), EGPI Firecreek Inc. (OTCBB: EFIR), Pluristem Therapeutics Inc. (Nasdaq: PSTI), BioSante Pharmaceuticals Inc. (Nasdaq: BPAX), MYOS Corp. (OTCBB: MYOS) and Nexxus Lighting Inc. (NASDAQ: NEXS).
BRAZOS INTERNATIONAL EXPLORATION INC. (OTC: BRZL)
"Up 200.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BRZL.php
Brazos International Exploration, Inc. engages in the acquisition and exploration of mineral properties in Canada. It primarily explores for uranium, gold, and silver ores. The company holds an option to acquire 100% interest in various mineral claims located in the Laurentides Region near Mont Laurier, Quebec. Brazos International Exploration, Inc. was founded in 2007 and is based in Brooklyn, New York.
BRZL News:
No recent news for Brazos International Exploration, Inc. (OTCBB: BRZL).
EGPI FIRECREEK INCORPORATED (OTCBB: EFIR)
"Up 100.00% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/EFIR.php
EGPI Firecreek, Inc.'s business and acquisition strategy is focused on producing oil and gas. The Company puts emphasis on acquiring existing fields with proven reserves or by the rehabilitation of oilfields with potentially high throughput. Through its wholly owned subsidiary Energy Producers, Inc., it acquires resource properties and inventories. Through its wholly owned subsidiary Chanwest Resources, LLC it operates as an oil and gas service business. EGPI Firecreek, Inc. is also planning to expand into producing energy through alternative energy sources through their recently acquired Arctic Solar Engineering subsidiary.
EFIR News:
August 3 - Mondial Ventures, Inc. Completes First Of Several Planned Acquisitions For Working Interest In Producing Oil And Gas Properties In West Texas
Acquisition To Include A Work Program To Increase Production And Future Drilling Programs On Additional Properties
Mondial Ventures, Inc. (OTC: MNVN) is pleased to announce the acquisition of a working interest for the oil producing property J.B. Tubb Leasehold Estate/Amoco Crawar Field, North 40 with additional related equipment from EGPI Firecreek, Inc. (OTCBB: EFIR).
Terms for the purchase of the North 40 acres of the J.B. Tubb Leasehold Estate/Amoco Crawar field consists of a 37.5% working interest ("WI"), 28.125% net revenue interest ("NRI") in the oil and gas interests, and pro rata oil & gas revenue and reserves for all depths below the surface to 8500 ft. including all related assets, fixtures, equipment, three well heads and three well bores. The field is located in the Permian Basin and the Crawar Field, which is directly adjacent to property operated by Chevron Corporation in Ward County, Texas (12 miles southeast of Monahans and 30 miles west of Odessa in West Texas). Based on engineering reports, the working and net revenue interests carry a gross value of $1,150,000. Currently, there are three wells in operation on the property currently producing approximately 300+ barrels of oil per month. Plans are to immediately increase and stabilize oil and natural gas production, thereby increasing initial production to approximately 900 to 1000 barrels of oil per month, with additional anticipated oil production increases, as the remedial work programs progress. The purchase also includes the Highland Production Company No. 2 well-bore in the oil and gas interests and pro rata oil & gas revenue and reserves with depth of ownership from 4700 ft. to 4900 ft.
This property is located and is part of the Crawar field, which is currently considered to be one of the most prolific oil & gas fields in West Texas. Several major oil companies have already established several ongoing drilling projects in this large field. Present Crawar field statistics show overall production capabilities of 500,000 barrels of oil and 4.6 BCF of natural gas per month respectively.
Additional terms for the purchase include an option to develop and drill a series of wells on the J.B. Tubb Leasehold Estate/Amoco Crawar Field, South 40. The following formations are currently available for oil & gas drilling considerations in the South 40 acreage: Glorietta, Upper Clearfork, Tubbs, Lower Clearfork, Witchita Albany, Wolfcamp, Detrital Zone and Waddell formations.
Mondial Ventures initially plans to exercise one of its options by providing $1.575 million, raised on a best efforts basis, for Capital Expenditures ("CAPEX"), for the drilling of an Ellenburger Well located on the South 40 acreage. The work program calls for drilling down to an 8,300 ft. depth on a turn-key basis. Public Records reveal an average production rate of 240 barrels of oil per day for Ellenburger wells on properties adjacent to the South 40 acreage that are currently owned by Chevron, BP and McCulloch Oil Corp. of California.
Further details about the transaction are disclosed in the Companies 8K and 14F-1 filings.
ABOUT MONDIAL VENTURES, INC.
Mondial Ventures, Inc. is engaged in the acquisition of Oil and Gas properties and assets that can be developed into revenue producing assets. The Company has put an emphasis on acquiring existing Oil fields with proven reserves or by the rehabilitation of oilfields with potentially high throughput.
PLURISTEM THERAPEUTICS INCORPORATED (NASDAQ: PSTI)
"Up 14.80% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/PSTI.php
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
PSTI News:
August 6 - Life of Cancer Patient Suffering From Bone Marrow Failure Saved Following Treatment With Pluristem's PLX Cells
Recently Released From Hadassah Medical Center Hospital, Patient Becomes Second Person Whose Life Was Saved by PLX Cells, Joining Seven Year Old Girl Who Suffered From Severe Aplastic Bone Marrow
Pluristem Therapeutics, Inc. (Nasdaq: PSTI), a leading developer of placenta-based cell therapies, announced today that the life of a patient suffering from bone marrow failure in which there was a dangerous reduction in the number of red blood cells, white blood cells, and platelets (pancytopenia) has been saved using Placental eXpanded (PLX) cells. This is the second time in the past three months that a patient suffering from bone marrow failure was successfully treated in a compassionate use treatment with PLX cells with a return of bone marrow function.
The patient, a 54 year-old woman diagnosed with lymphoma cancer, was initially treated with chemotherapy. Her condition continued to deteriorate, necessitating a bone marrow transplant. The transplant, as well as alternate therapies, were not successful. As a result, the woman suffered from prolonged dangerous pancytopenia. PLX cells were then administered to the patient at the Hadassah Medical Center, Jerusalem, under the Israeli government's compassionate use program. Following the injection of the PLX cells intramuscularly (IM), the woman's clinical condition and blood counts improved to the point where the patient was able to be released from the isolation unit and subsequently discharged from the hospital.
"This is a real breakthrough -- the woman was in isolation due to low white blood cells and high susceptibility to infections and in addition her red blood cells and platelets were low, leading to a very dangerous and life-threatening situation," said Professor Reuven Or, Director of Bone Marrow Transplantation and Cancer Immunology at Hadassah Medical Center. "Further, autologous bone marrow transplantation that she received engrafted poorly, and as a last resort, we applied for a compassionate treatment using Pluristem's PLX cells based on our previous experience with those cells. The treatment with PLX has saved her life and can certainly be classified as a medical miracle," added Dr. Reuven Or. "The result of this unique case demonstrates that PLX cells could potentially be effective for use in cancer patients, who receive bone marrow transplantation following severe radiation and chemotherapy treatments, which severely damage their bone marrow."
The clinical improvements observed in this and a previous patient treated with PLX cells demonstrate that these cells could potentially assist in the recovery of bone marrow following bone marrow transplant failure or other conditions where the bone marrow is significantly compromised.
Pluristem recently announced it is preparing to apply for Orphan Drug Status for its PLX cells with the U.S. Food and Drug Administration for the treatment of aplastic bone marrow. The bone marrow transplant market is an estimated $1.3 billion per year in the U.S. alone, based on 30,000 bone marrow transplants in the U.S per annum.
In May, Pluristem announced that a seven year-old girl, whose condition was rapidly deteriorating due to an aplastic bone marrow, experienced a reversal of her condition with a significant increase in her red blood cells, white blood cells and blood platelets following the intramuscular injection of the company's PLX cells. The patient has subsequently been released from the hospital and returned home.
"We are extremely grateful to be working with Professor Reuven Or and his team, whose work helped save the life of this woman," said Zami Aberman, Chairman and CEO of Pluristem. "Pluristem now has several clinical data points to suggest that our PLX cells are successful in treating patients whose bone marrow is failing."
ABOUT THE PATIENT
This 54 year-old patient was diagnosed with lymphoma in 2008 and received chemotherapy, resulting in remission of the disease in 2009. At that point, doctors collected stem cells from her bone marrow. The cancer returned to her spinal cord in 2011. She was treated with both radiation and chemotherapy, which damaged her bone marrow. Autologous stem cell therapy was administered with cells collected from her in 2009. The bone marrow engrafted poorly and she was not responding to alternate treatments. Forty-five days after the autologous stem cell transplantation, with the patient's clinical condition deteriorating, PLX cells were administered IM via two courses a week apart. Approximately two weeks after her second course of PLX cells, clinical improvement was noted with an increase in her red blood cells, white blood cells and platelets. Her clinical condition has improved significantly to the point that she was released from the hospital.
BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX)
"Up 20.80% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
BPAX News:
August 1 - BioSante Pharmaceuticals Reports Second Quarter Financial Results and Pipeline Update
BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) reported on its cash balance as of June 30, 2012, its financial results for the second quarter of 2012 and provided an update on the Company’s pipeline.
The Company’s cash and cash equivalents as of June 30, 2012 were approximately $42.4 million. BioSante incurred a net loss of approximately $7.3 million or ($0.36) per share for the quarter ended June 30, 2012, compared to a net loss of $15.0 million or ($0.96) per share for the same period in 2011. The decrease in the net loss was due primarily to lower expenses associated with the clinical development of LibiGel® (testosterone gel) as a result of the conclusion of the prior two Phase III efficacy trials; the LibiGel Phase III cardiovascular event and breast cancer safety study continues.
Pipeline Update
A Phase II open label study titled, “Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission,” is recruiting subjects for treatment with the combination of BioSante’s GVAX Myeloma vaccine and lenalidomide (Revlimid®; Celgene). Estimated enrollment is 15 subjects. The primary endpoint of the study is improvement in the clinical response of subjects by adding GVAX Myeloma vaccine to subjects already receiving lenalidomide.
BioSante is continuing the development of two new LibiGel Phase III efficacy trials, and intends to provide additional trial design information and timing of trial initiation, as appropriate. As stated previously, BioSante intends to apply for an FDA Special Protocol Assessment (SPA) agreement prior to initiating the efficacy trials. It is expected that any new efficacy trials will include the same FDA-required efficacy endpoints as prior Phase III efficacy trials: an increase in the number of satisfying sexual events and sexual desire, and decreased distress associated with low desire. BioSante targets an SPA agreement by year-end.
The ninth unblinded review of safety data from the LibiGel Phase III safety study by the independent Data Monitoring Committee (DMC) is expected to occur during the third quarter 2012. BioSante remains blinded to all safety data in the Phase III safety study.
BioSante’s testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals, was approved by the FDA in the first quarter 2012. Teva is responsible for all regulatory and marketing activities. Patent litigation between Teva and Abbott Laboratories, a marketer of a testosterone for men, was settled in December 2011; however terms of the settlement agreement are confidential and have not been disclosed publicly. A launch date has not been announced. According to IMS, the current U.S. market for male testosterone products is estimated at over $1.6 billion.
MYOS CORPORATION (OTCBB: MYOS)
"Up 29.23% on Monday"
Detailed Quote: http://www.otcpicks.com/quotes/MYOS.php
MYOS Corporation is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance.
MYOS News:
July 12 - MYOS Issues Special Letter to Shareholders: Company Committed to R&D, Developing Innovative Products and Formulations
MYOS Corporation's (OTCBB: MYOS) Board of Directors today issued the following Letter to Shareholders:
Dear Shareholder:
Your MYOS Board of Directors is pleased to report that it has successfully delivered on several important developmental steps in the first seven months of 2012, and is moving continuously forward with new research and operational initiatives to accelerate our drive in becoming the leader in muscle health.
The first half of 2012 was an important building period for MYOS Corporation. As with any early stage company, the first few quarters of operations are generally consumed by building infrastructure, developing strategy and financial planning. While a priority, execution of the business plan often occurs incrementally. One such initial step was to strengthen our balance sheet, and we are pleased to say we have done so and eliminated virtually all MYOS debt.
We also completed the negotiation and execution of our first commercial distribution agreement for our first product — MYO-T12™ — that launches next month. In preparation of the MYO-T12 production and sales volume planned, we have upgraded our manufacturing processes and supply chain logistics to meet the industry's highest quality control standards. We have also improved efficiencies and thereby reduced costs.
Looking forward, we are committed to developing innovative products and formulations that strengthen our position in muscle health. MYOS is collaborating with a highly respected research and development company analyzing the science of the active peptide components found in the Company's first product MYO-T12. In parallel, we are also engaged in early research evaluating the regulatory protein myostatin as a potential target for other therapeutic products. We believe both these research initiatives will provide new insights regarding the formulation and delivery of the active ingredients in MYO-T12.
Additionally, we are negotiating with a leading U.S. university on the parameters of what would be the largest clinical trial on MYO-T12 to date, and also with a contract research organization to study our proprietary bio tech for application in the treatment of the chronically ill. We expect these coordinated, multiple research efforts will enable us to develop a stronger intellectual property portfolio and bio tech platform.
Perhaps our most important 2012 accomplishment to date, which enhances our prospects for future success, was last month's successful completion of a $5.6 million private equity financing. We believe this financing, which included institutional and private accredited investors, positions us to execute on our ambitious business plan and more fully exploit our commercial and research relationships.
The first seven months of 2012 have been an exciting foundation building period at MYOS, and we are more confident than ever in our ability to deliver on MYOS' mission to become the leader in muscle health. The entire MYOS team is a firm believer in the words of Thomas Edison: "Great ideas originate in the muscles."
Sincerely yours,
MYOS Board of Directors
NEXXUS LIGHTING INCORPORATED (NASDAQ: NEXS)
"Up 14.94% on Monday"
Detailed Quote: www.otcpicks.com/quotes/NEXS.php
Nexxus Lighting, Inc. engages in the design, manufacture, marketing, and sale of light emitting diode (LED) replacement light bulbs; and LED-based signage, channel letter, and contour lighting products in the United States, Canada, and internationally. The company offers white light LED replacement lamps, and LED signage and lighting strips for use in commercial, hospitality, institutional, retail, and sign markets. It also provides LED signage and lighting strips for non-signage applications, such as vending machines, illuminated display tables, and architectural applications. The company sells its products under the Array Lighting and Lumificient brand names. Nexxus Lighting, Inc. markets and distributes its products through a network of independent sales representatives and distributors, as well as through energy savings companies and national accounts. The company was formerly known as Super Vision International, Inc. and changed its name to Nexxus Lighting, Inc. in April 2007. Nexxus Lighting, Inc. was founded in 1991 and is headquartered in Charlotte, North Carolina.
NEXS News:
No recent news for Nexxus Lighting, Inc. (NASDAQ: NEXS).
|
